Global Radiopharmaceutical Theranostics & Alpha-Emitter Oncology Market — Intelligence Report

Radiopharmaceutical oncology has moved out of the specialist nuclear medicine corner and into the center of precision cancer treatment. The market is being pulled by two forces at once: commercial uptake of beta-emitting radioligand therapies in prostate cancer and neuroendocrine tumors, and a fast-forming alpha-emitter pipeline aimed at deeper, more durable tumor cell kill. Nexvora Intelligence estimates the global radiopharmaceutical theranostics and alpha-emitter oncology market at approximately $•••–••• billion in 2025, with therapeutic products accounting for the majority of value and diagnostics acting as the clinical gateway.

The near-term market is still concentrated. Prostate cancer, especially PSMA-targeted imaging and therapy, is the anchor indication; neuroendocrine tumors remain a proven but smaller base. That concentration is not a weakness yet. It gives the sector a repeatable commercial model: identify target expression, image the patient, treat with a paired radioligand, monitor response, and retreat where clinically appropriate. The bigger question is whether this model scales into larger solid tumors without losing the operational discipline that made the first wave investable.

Alpha-emitter oncology is the most contested growth pocket. Actinium-225, lead-212, radium-223, thorium-227, and other platforms offer high-energy, short-path radiation that can be particularly attractive in micrometastatic and resistant disease settings. Commercial revenue remains modest today, but pipeline intensity is high and deal activity reflects a clear strategic belief: if targeting, dosimetry, manufacturing, and safety can be controlled, alpha therapies could command premium positioning in later-line and eventually earlier-line oncology.

The limiting factor is not demand. It is execution. Isotope availability, radiochemistry yield, shelf-life constraints, treatment-site readiness, reimbursement coding, waste handling, and trained nuclear medicine capacity all sit between a promising asset and repeatable revenue. Companies that treat manufacturing and distribution as a strategic moat, not a back-office function, are likely to separate from weaker peers as volumes rise.

Nexvora Intelligence developed this opening assessment using proprietary market modeling, indication-level adoption curves, therapy pricing assumptions, diagnostic utilization estimates, and regional nuclear medicine capacity analysis.

The model evaluates therapeutic radiopharmaceuticals, companion imaging agents, targeted alpha therapy platforms, isotope supply constraints, and treatment-site activation dynamics across major oncology markets.

All market figures in this report opening are Nexvora modeled estimates, as no external evidence was retrieved for this request.

Forecast ranges reflect scenario-based assumptions around regulatory approvals, isotope availability, reimbursement progression, clinical uptake, and expansion beyond prostate cancer and neuroendocrine tumors.